

# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2021- 22/007

May 20, 2021

To,

Listing Department

**BSE Ltd**

1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001.

Scrip Code: 532637

Listing Department

**National Stock Exchange of India Limited**

"Exchange Plaza", 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai - 400 051

Symbol: MANGALAM

**Sub: Outcome of the Board Meeting held on Thursday, May 20, 2021**

Dear Sir / Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we have to inform you that the Board of Directors of the Company, in their meeting held today i.e., Thursday, May 20, 2021 has *inter-alia* approved the Audited Financial Results (Standalone) for the quarter and year ended March 31, 2021 pursuant to Regulation 33 of the Listing Regulations. A copy of the said results, notes thereto and Auditor's Report is enclosed for your records.

We hereby declare that the Auditors have expressed a modified opinion in the Audit Report on the Standalone Audited Financial Results for the quarter and year ended March 31, 2021 and as required we submit the Annexure – I in the prescribed format thereby furnishing Statement of impact of Audit Qualifications (for Audit Report with modified opinion).

Further please note that the Company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations.


# Mangalam Drugs and Organics Ltd.





Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

The meeting of Board of Directors of the Company commenced at 2:30 P.M. and concluded at 4:10 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,  
For Mangalam Drugs & Organics Limited

Govardhan M. Dhool  
Chairman & Managing Director  
DIN: 01240086



**Audited Financial Results for the Year Ended 31st March 2021 approved and taken on record by the Board at their meeting dated 20th May, 2021**

					(Rs. In Lacs)	
Sr.No	Particulars	Quarter Ended			Year Ended	
		31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
		Audited	Unaudited	Audited	Audited	Audited
<b>A) Part-1 Statement of Audited Financial Results for the Year Ended March 31, 2021</b>						
1	<b>Revenue from Operations</b>	9,078.70	8,868.73	8,809.46	38,014.06	28,235.36
2	Other Income	211.38	126.78	45.33	472.06	118.12
3	<b>Total Revenue(1+2)</b>	<b>9,290.08</b>	<b>8,995.51</b>	<b>8,854.79</b>	<b>38,486.12</b>	<b>28,353.48</b>
4	<b>Expenses</b>					
	(a) Cost of Materials Consumed	5,468.93	5,354.36	5,279.54	25,601.72	17,807.14
	(b) Purchase of Stock in trade	0.00	0.00			0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	679.82	278.35	1,084.22	(423.26)	1,727.66
	(d) Employee Benefits Expenses	846.96	741.19	705.66	2,987.95	2,604.41
	(e) Finance Costs	221.57	234.82	246.29	932.61	1,040.47
	(f) Depreciation & amortization expenses	251.53	233.36	209.61	917.53	821.78
	(g) Other Expenses	1,137.15	1,234.50	1,024.11	4,517.67	3,726.81
	<b>Total Expenses</b>	<b>8,605.96</b>	<b>8,076.58</b>	<b>8,549.43</b>	<b>34,534.22</b>	<b>27,728.27</b>
5	<b>Profit / (Loss) before exceptional &amp; extraordinary items and tax(3-4)</b>	<b>684.12</b>	<b>918.93</b>	<b>305.36</b>	<b>3,951.91</b>	<b>625.21</b>
6	<b>Exceptional items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
7	<b>Profit/(Loss) before extraordinary items and tax (5-6)</b>	<b>684.12</b>	<b>918.93</b>	<b>305.36</b>	<b>3,951.91</b>	<b>625.21</b>
8	<b>Extraordinary Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
9	<b>Profit(+)/Loss (-) before tax(7-8)</b>	<b>684.12</b>	<b>918.93</b>	<b>305.36</b>	<b>3,951.91</b>	<b>625.21</b>
10	<b>Tax Expenses</b>					
	Current Tax	152.41	204.42	34.69	926.78	110.10
	Less: MAT credit entitlement / reversal	88.25	71.09	(29.33)		(104.74)
	Deferred Tax	228.04		(205.40)	228.04	(205.40)
11	<b>Net Profit(+)/Loss(-) after Tax (9-10)</b>	<b>215.42</b>	<b>643.42</b>	<b>505.40</b>	<b>2,797.09</b>	<b>825.25</b>
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	5.51	(33.42)	0.32	(94.77)	2.32
13	<b>Total Comprehensive Income</b>	<b>220.93</b>	<b>610.00</b>	<b>505.72</b>	<b>2,702.31</b>	<b>827.57</b>
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				11,513.36	8,811.05
16	<b>Earnings Per Share (EPS) (of Rs 10/-each not annualised):</b>					
	(a) Basic	1.36	4.07	3.19	17.67	5.21
	(b) Diluted	1.36	4.07	3.19	17.67	5.21

**Notes :**

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on May 20, 2021. The Statutory Auditors have expressed an modified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Code on Social Security, 2020('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent December 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the code becomes effective.
- Hon'ble Securities Appellate Tribunal granted the interim reliefs vide its Order dated December 10, 2020 (SAT Interim Order) by directing that the effect and operation of the order passed by Securities and Exchange Board of India (SEBI) through its whole-time member dated September 22, 2020 shall remain stayed provided the Company and entities / individuals part of the promoter and promoter group (appellants) deposit a sum of Rs. 25 Lakhs before the SEBI within 4 (four) weeks from the date of SAT Interim Order. The amount so deposited shall be subject to the result of the appeal. The application for stay filed by appellants was disposed of. Accordingly, Appellants had deposited a sum of Rs. 25 Lakhs before the SEBI (including Rs. 2.92 Lakhs deposited by the Company). The final decision in the matter is awaited.
- The figures for the quarter ended 31st March, 2021 and 31st March, 2020 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

PARAG  
RAMAN  
HANGEKAR

Digitally signed by  
PARAG RAMAN  
HANGEKAR  
Date: 2021.05.20  
15:38:38 +05'30'

Place: Mumbai  
Date: 20th May, 2021

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN:01240086)





Statement of Assets and Liabilities		
Particulars	Rs. in Lacs	Rs. in Lacs
	As at 31.03.2021 Audited	As at 31.03.2020 Audited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment	10360.93	9329.20
(b) Capital Work-In-Progress	635.18	124.03
(c) Intangible assets	847.39	613.59
(d) Lease assets	591.10	164.13
(e) Financial Assets		
(i) Investments	22.35	22.35
(ii) Other Financial Assets	246.21	236.18
(iii) Deferred Tax Asset (Net)		
(f) Non Current Tax Assets (Net)		
(g) Other Non-current Assets	383.90	659.75
<b>Total Non-current Assets (A)</b>	<b>13087.07</b>	<b>11,149.23</b>
<b>B. Current Assets</b>		
(a) Inventories	5858.75	6484.27
(b) Financial Assets		
(i) Trade Receivables	5359.14	3998.29
(ii) Cash and Cash Equivalents	59.18	162.91
(iii) Bank Balance other than Cash and Cash Equivalents		
(iv) Loans	0.91	0.96
(v) Others Financial Assets		
(c) Other Current Assets	1919.73	1271.04
<b>Total Current Assets (B)</b>	<b>13197.71</b>	<b>11,917.48</b>
<b>TOTAL ASSETS</b>	<b>26284.77</b>	<b>23,066.71</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	11513.36	8811.05
<b>Total Equity (A)</b>	<b>13096.18</b>	<b>10,393.88</b>
<b>B. Non-Current Liability</b>		
(a) Financial Liabilities		
(i) Borrowings	687.64	417.28
(b) Deferred Tax Liabilities (Net)	1417.86	1228.76
(c) Lease Liability	318.96	80.05
(d) Deposits Taken	0.05	0.05
(e) Provisions		
(f) Other Non-Current Liabilities		
<b>Total Non-current Liabilities (B)</b>	<b>2424.51</b>	<b>1,726.13</b>
<b>C. Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	5118.16	4186.08
(ii) Lease Liability	255.31	113.54
(ii) Trade Payables		
Payable to MSME	551.54	243.31
Others	3716.32	5416.03
(iii) Other Financial Liabilities	590.58	400.40
(b) Other Current Liabilities	491.80	504.78
(c) Provisions	40.36	82.56
<b>Total Current Liabilities (C)</b>	<b>10764.08</b>	<b>10,946.70</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>26284.77</b>	<b>23,066.71</b>

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

PARAG  
RAMAN  
HANGEKAR

Digitally signed by  
PARAG RAMAN  
HANGEKAR  
Date: 2021.05.20  
15:39:12 +05'30'

Place: Mumbai  
Date: 20th May, 2021

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN:01240086)



## MANGALAM DRUGS AND ORGANICS LIMITED



## Cash Flow Statement For The Period Ended March 31, 2021

(Rupees In Lacs)

Particulars	For the Period ended March 31, 2021 Audited	For the Period ended March 31, 2020 Audited
<b>A. Cash flow from operating activities</b>		
Net profit before tax and extra ordinary items.	3,951.91	625.21
<b>Add / (Less) :</b>		
Depreciation & amortisation	917.53	821.78
Interest expenses	932.61	1,040.47
Dividend Income	-	(0.04)
(Gain)/loss on sale of fixed assets	7.35	5.36
(Gain)/loss on sale of investments	-	-
Net gain arising on financial assets measured at fair value through profit or loss	-	-
Remeasurements of the defined benefit plans	(133.71)	3.22
<b>Operating profit before working capital changes</b>	<b>5,675.69</b>	<b>2,496.00</b>
<b>Adjustment for :</b>		
(Increase)/decrease in short term loans and advances	0.05	(0.09)
(Increase)/decrease in other current assets	(648.69)	(19.68)
(Increase)/decrease in trade receivables	(1,360.84)	(2,235.22)
(Increase)/decrease in inventory	625.51	861.05
(Increase)/decrease in other non-current assets	265.82	(657.55)
Increase/(decrease) in Other Equity	-	-
Increase/(decrease) in trade payables	(1,391.47)	2,417.99
Increase/(decrease) in other current liabilities	177.20	212.66
Increase/(decrease) in provisions	(42.20)	23.46
Increase/(decrease) in current lease liabilities	141.77	76.24
Increase/(decrease) in deposits	0.00	0.05
Increase/(decrease) in non current lease liabilities	238.91	(114.85)
	<b>(1,993.94)</b>	<b>564.07</b>
<b>Cash generated from operations</b>	<b>3,681.75</b>	<b>3,060.07</b>
<b>Add / ( Less) :</b>		
Income Tax (Paid)/ Refund	(926.78)	(5.36)
<b>Net cash from operating activities</b>	<b>2,754.97</b>	<b>3,054.71</b>
<b>B. Cash flow from investing activities :</b>		
Purchase of fixed assets including Capital WIP	(3,143.61)	(693.19)
Sale of fixed assets	15.08	4.24
Sale/(Purchase) of investments	-	1.66
Divided Income	-	0.04
<b>Net cash from investing activities</b>	<b>(3,128.53)</b>	<b>(687.25)</b>
<b>C. Cash flow from financing activities :</b>		
Proceeds/(repayment) of short term borrowing	932.08	(865.12)
Proceeds/(repayment) of long term borrowing	270.36	(442.28)
Interest Paid	(932.61)	(1,040.47)
Dividend paid	-	-
Issue of Share	-	-
<b>Net cash used in financing activities</b>	<b>269.83</b>	<b>(2,347.88)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(103.73)</b>	<b>19.58</b>
<b>Cash and cash equivalents - opening balance</b>	<b>162.91</b>	<b>143.34</b>
<b>Cash and cash equivalents - closing balance</b>	<b>59.18</b>	<b>162.91</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>		
- Cash in hand	5.73	6.48
- Balance in current & fixed deposit accounts	53.45	156.43
<b>Total</b>	<b>59.18</b>	<b>162.91</b>

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

PARAG  
RAMAN  
HANGEKAR

Digitally signed by  
PARAG RAMAN  
HANGEKAR  
Date: 2021.05.20  
15:39:37 +05'30'

Place: Mumbai

Date: 20th May, 2021

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)  
Chairman & Managing Director  
(DIN: 01240086)





Auditors' Report on Audited Standalone Quarterly Financial Results and Year to date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

## INDEPENDENT AUDITORS' REPORT

### TO THE BOARD OF DIRECTORS OF MANGALAM DRUGS & ORGANICS LIMITED

#### Qualified Opinion

We have audited the accompanying standalone financial results of Mangalam Drugs and Organics Limited (the company) for the quarter ended March 31, 2021 and the year to date results for the period from April 01, 2020 to March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us except for the para mentioned below in Basis for Qualified Opinion:

- a) these standalone financial results are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard
- b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended March 31, 2021 as well as the year to date results for the period from April 01, 2020 to March 31, 2021.

#### Basis for Qualified Opinion

Company has capitalised two vehicles amounting to Rs 1.32 Crores in the names of Individual Directors and being co-applicant has also disclosed the corresponding loans as its liabilities, One of the Non - Executive Director has resigned during the year. Since the ownership of the vehicles are not in the name of the Company, hence the assets of the Company are overstated to the extent of Rs. 0.95 crores net of Depreciation and down-payment, Liabilities are overstated to the extent of Rs 0.84 crores and the net profit is understated by Rs. 0.11 crores.

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditors' Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code



#### BRANCHES :

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478  
DELHI : 505, Nirmal Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200

of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Emphasis of Matter Paragraph**

- a) Due to the prevailing lockdown and restrictions over travelling, Company has not been able to obtain the actuarial valuation report from the actuary towards the Gratuity and Leave encashment and accordingly the said liabilities have been provided proportionately based on the previous year's actuarial reports.
- b) Balances of debtors/creditors/loans and advances are subject to confirmation and reconciliation. Management has confirmed that the final impact upon confirmation and reconciliation would not be material.
- c) We draw attention to Note No. 5 which states that "Hon'ble Securities Appellate Tribunal granted the interim reliefs vide its Order dated December 10, 2020 (SAT Interim Order) by directing that the effect and operation of the order passed by Securities and Exchange Board of India (SEBI) through its whole-time member, dated September 22, 2020 shall remain stayed provided the Company and entities / individuals part of the promoter and promoter group (appellants) deposit a sum of Rs. 25 Lakhs before the SEBI within 4 (four) weeks from the date of SAT Interim Order. The amount so deposited shall be subject to the result of the appeal. The application for stay filed by appellants was disposed of. Accordingly, Appellants had deposited a sum of Rs. 25 Lakhs before the SEBI (including Rs. 2.92 Lakhs deposited by the Company). The Final decision in the matter is awaited."

Our opinion is not modified in respect of the above matters.

#### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair

view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the



Board of Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditors' Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d) Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all





relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**Other Matter**

- a) The financial statements of the Company as on 31 March, 2021 were audited under exceptional circumstances due to prevailing lockdown conditions on account of COVID-19 pandemic. Documentation and other requirements along with discussion with the Management were held through video conference and discussed over other electronic modes.
- b) Due to COVID-19 related lockdown we were not able to participate in physical verification of inventory that was carried out by management. Consequently, we have performed alternate audit procedures to audit the existence of inventory as per the guidance provided in SA 501 "Audit Evidence- Specific Consideration for selected items" and have obtained sufficient appropriate audit evidence to issue our opinion on these standalone financial results.
- c) The standalone financial results include the results for Quarter ended March 31, 2021 being the balancing figures between the audited figures in respect of full financial year and the published unaudited year to date figures up-to the third quarter of the current financial year, which were subject to limited review by us.

**For Batliboi & Purohit**  
**Chartered Accountants**  
**Firm Registration No.: 101048W**

PARAG  
RAMAN  
HANGEKAR

Digitally signed by  
PARAG RAMAN  
HANGEKAR  
Date: 2021.05.20 15:29:42  
+05'30'



**Parag Hangekar**  
**Partner**  
**Membership No:110096**  
**UDIN: 21110096AAAACJ1843**

**Date: May 20, 2021**  
**Place: Mumbai**

# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 ✉ contactus@mangalamdrugs.com

## ANNEXURE I

Statement on Impact of Audit Qualifications (for audit report with modified opinion) submitted along-with Annual Audited Financial Results - (Standalone)

(Rupees in Lacs)

Statement on Impact of Audit Qualifications for the Financial Year ended March 31, 2021				
[See Regulation 33 / 52 of the SEBI (LODR) (Amendment) Regulations, 2016]				
I.	Sl. No.	Particulars	Audited Figures (as reported before adjusting for qualifications)	Adjusted Figures (audited figures after adjusting for qualifications)
	1.	Turnover / Total income	38486.12	38486.12
	2.	Total Expenditure	34534.22	34523.48
	3.	Net Profit/(Loss)	2797.09	2807.83
	4.	Earnings Per Share	17.67	17.74
	5.	Total Assets	26284.77	26189.98
	6.	Total Liabilities	26284.77	26189.98
	7.	Net Worth	-	-
	8.	Any other financial item(s) (as felt appropriate by the management)	-	-
II.	<b>Audit Qualification (each audit qualification separately):</b>			
	a.	<b>Details of Audit Qualification:</b> Company has capitalized two vehicles amounting to Rs 1.32 Crores in the names of Individual Directors and being co-applicant has also disclosed the corresponding loans as its liabilities, One of the Non - Executive Director has resigned during the year. Since the ownership of the vehicles are not in the name of the Company, hence the assets of the Company are overstated to the extent of Rs. 0.95 crores net of Depreciation and down-payment, Liabilities are overstated to the extent of Rs 0.84 crores and the net profit is understated by Rs. 0.11 crores.		
	b.	<b>Type of Audit Qualification :</b> Qualified Opinion		
	c.	<b>Frequency of qualification:</b> first time		
	d.	<b>For Audit Qualification(s) where the impact is quantified by the auditor, Management's Views:</b> Company has acquired two vehicles for the purpose of business and registered under Motor Vehicle Act, 1988 in the name of the director. These vehicles are used for the purpose of business only The purchase of the vehicles are as per the contractual obligation of the Company with the directors hence it has been capitalized in the books of account. The payments are made by the Company being the beneficial owner of the asset hence depreciation has been charged by the Company in its books of account. On resignation of the one of the directors of the Company, it is in the process of getting the ownership transferred in its own name.		
	e.	<b>For Audit Qualification(s) where the impact is not quantified by the auditor: NA</b>		
		<b>(i) Management's estimation on the impact of audit qualification: NA</b>		
		<b>(ii) If management is unable to estimate the impact, reasons for the same: NA</b>		
		<b>(iii) Auditors' Comments on (i) or (ii) above: NA</b>		

Factory : 1. Plot No. 117, 2nd Phase, G. I. D. C., VAPI, Dist. Valsad - 396195 (Gujarat)

Phone : 91 - 0260 - 2430598 • Fax : 91 - 0260 - 2431919 • mdol1@managalamdrugs.com

Factory : 2. Plot No. 1203, 3rd Phase, G. I. D. C., VAPI, Dist. Valsad - 396195 (Gujarat) • Phone : 91 - 0260 - 2432669 / 2432669

Fax : 91 - 0260 - 2432669 • Email : mdol2@mangalamdrugs.com • CIN : L24230MH1972PLC116413








# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 ☎ contactus@mangalamdrugs.com

III.	<b>Signatories:</b>	
	• CEO/Managing Director	
	• CFO	
	• Audit Committee Chairman	Sd/-
	• Statutory Auditor	PARAG RAMAN HANGEKAR Digitally signed by PARAG RAMAN HANGEKAR Date: 2021.05.20 15:40:45 +05'30'
	<b>Place:</b> Mumbai	
	<b>Date:</b> 20/05/2021	



\* Due to COVID-19 pandemic, the Board Meeting was conducted through online mode. The Audit Committee Chairman was attending the meeting from his residence at Mumbai and he doesn't have Digital Signature. Hence, the statement of impact on audit qualification is signed as sd/- by Audit Committee Chairman.

**Factory : 1.** Plot No. 187, 2nd Phase, G. I. D. C., VAPI, Dist. Valsad - 396195 (Gujarat)

Phone : 91 - 0260 - 2430598 • Fax : 91 - 0260 - 2431919 • mdol1@managalamdrugs.com

**Factory : 2.** Plot No. 1203, 3rd Phase, G. I. D. C., VAPI, Dist. Valsad - 396195 (Gujarat) • Phone : 91 - 0260 - 2432669 / 2432669

Fax : 91 - 0260 - 2432669 • Email : mdol2@mangalamdrugs.com • CIN : L24230MH1972PLC116413